THDG3

About DeckTherapeutics

DeckTherapeutics is a private, preclinical-stage biotech based in Cambridge, USA, founded in 2021. The company is developing THDG3, a proprietary intravenous omega-3 fatty acid emulsion, as a neuroprotectant for acute brain injuries caused by oxygen deprivation. Its lead indication is neonatal hypoxic-ischemic encephalopathy (HIE), with ischemic stroke as a secondary target, addressing significant unmet medical needs where no neuroprotectants are currently approved. The technology platform originated from research at Columbia University.

About DeckTherapeutics

DeckTherapeutics is a private, preclinical-stage biotech based in Cambridge, USA, founded in 2021. The company is developing THDG3, a proprietary intravenous omega-3 fatty acid emulsion, as a neuroprotectant for acute brain injuries caused by oxygen deprivation. Its lead indication is neonatal hypoxic-ischemic encephalopathy (HIE), with ischemic stroke as a secondary target, addressing significant unmet medical needs where no neuroprotectants are currently approved. The technology platform originated from research at Columbia University.

Therapeutic Areas

Other Neonatal Hypoxic-Ischemic Encephalopathy (HIE) Drugs